NCT07034274

Brief Summary

A non-interventional, national longitudinal multicenter study of CV secondary prevention in Tunisia

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 9, 2025

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

June 15, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 24, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2025

Completed
Last Updated

June 24, 2025

Status Verified

June 1, 2025

Enrollment Period

2 months

First QC Date

June 15, 2025

Last Update Submit

June 15, 2025

Conditions

Secondary PreventionCHDCV Risk

Keywords

Secondary PreventionSTCCCVCHDCV Risk

Outcome Measures

Primary Outcomes (1)

  • Compliance

    Number of subjects with sufficient adherence to their cardiovascular medication

    From enrollment to the end of the follow-up (12 months)

Study Arms (1)

Coronary Event

Patient with any coronary event

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients who had a coronary event in 2024

You may qualify if:

  • Age \> 18 years and \< 80 years
  • Patients who have been hospitalized for at least one acute coronary event with coronary revascularization, either percutaneous or surgical by coronary artery bypass grafting, or who have confirmed coronary artery disease requiring optimal medical treatment for more than 6 months
  • Coronary event happening in 2024
  • Informed, read and signed consent

You may not qualify if:

  • Familial hypercholesterolemia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tunisian Society of Cardiology and Cardiovascular Surgery

Tunis, 1003, Tunisia

RECRUITING

Related Links

Study Officials

  • Youssef Ben Ameur, MD

    Tunisian Society of Cardiology and Cardiovascular Surgery

    STUDY CHAIR

  • Salma Charfeddine, MD

    Tunisian Society of Cardiology and Cardiovascular Surgery

    STUDY CHAIR

  • Ihsen Zairi, MD

    Tunisian Society of Cardiology and Cardiovascular Surgery

    STUDY CHAIR

Central Study Contacts

Salma Charfeddine, MD

CONTACT

+216 98638435selma_charfeddine@yahoo.fr

Ihsen Zairi, MD

CONTACT

+216 98555878ihsenzairi@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 15, 2025

First Posted

June 24, 2025

Study Start

June 9, 2025

Primary Completion

July 31, 2025

Study Completion

July 31, 2025

Last Updated

June 24, 2025

Record last verified: 2025-06

Locations

TU(1)